Trial reportBMC pregnancy and childbirth2013
A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED).
Trial report in BMC pregnancy and childbirth, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2015Pooled it
- Ceramides during Pregnancy and Obstetrical Adverse Outcomes.Metabolites · 2023Review
- Association between socioeconomic status with pregnancy and neonatal outcomes: An international multicenter cohort.Acta obstetricia et gynecologica Scandinavica · 2023Article
- Article
- Adherence to the infant vitamin D supplementation policy in Ireland.European journal of nutrition · 2021Article
- Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.Comprehensive Physiology · 2020Article
- Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test.PloS one · 2020Article
- Planning, Implementing, and Running a Multicentre Preterm Birth Study with Biobank Resources in Brazil: The Preterm SAMBA Study.BioMed research international · 2019Article
- Placental FKBP51 mediates a link between second trimester maternal anxiety and birthweight in female infants.Scientific reports · 2018Article
- Applications of Metabolomics in the Study and Management of Preeclampsia; A Review of the Literature.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- Generation and validation of a universal perinatal database and biospecimen repository: PeriBank.Journal of perinatology : official journal of the California Perinatal Association · 2016Article
- First trimester screening for pre-eclampsia.Obstetric medicine · 2016Review
- From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift.Current hypertension reports · 2015Review
- Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?Expert review of molecular diagnostics · 2015Review
- Risk factors and effective management of preeclampsia.Integrated blood pressure control · 2015Review
- Pre-eclampsia: an update.Current hypertension reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. METHODS/
designWe report the design of a multicentre, phase IIa clinical study aiming to recruit 5000 low risk primiparous women to assess and refine innovative prototype tests based on emerging metabolomic and proteomic technologies. Participation involves maternal phlebotomy at 15 and 20 weeks' gestation, with optional testing and biobanking at 11 and 34 weeks. Blood samples will be analysed using two innovative, proprietary prototype platforms; one metabolomic based and one proteomic based, both of which outperform current biomarker based screening tests at comparable gestations. Analytical and clinical data will be collated and analysed via the Copenhagen Trials Unit. DISCUSSION: The IMPROvED study is expected to refine proteomic and metabolomic panels, combined with clinical parameters, and evaluate clinical applicability as an early pregnancy predictive test for pre-eclampsia. If 'at risk' patients can be identified, this will allow stratified care with personalised fetal and maternal surveillance, early diagnosis, timely intervention, and significant health economic savings. The IMPROvED biobank will be accessible to the European scientific community for high quality research into the cause and prevention of adverse pregnancy outcome.
trial registrationTrial registration number NCT01891240The IMPROvED project is funded by the seventh framework programme for Research and Technological development of the EU. http://www.fp7-improved.eu/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.